Shin Nippon Biomedical Laboratories, Ltd.
Fiscal year ending March 2027 Q1 Financial Summary (Japan GAAP) (Consolidated)
Sales of 7,868 million yen for Q1, a quarterly high; operating income of 521 million yen, returning to profit. For the full-year 2027, revisions to the previously announced earnings guidance have been disclosed. Overseas orders surged, and the NR profit improvement was driven by revenue recognition from late-stage projects and foreign exchange gains.
Key Figures
- Sales: 7,868百万円
- Operating income: 521百万円
- Ordinary income: 1,433百万円
AI要約
Performance overview
In this first quarter, sales reached a record high led by the CRO business. Quarter-on-quarter sales increased and operating income turned to profitability. The commercialization delay of Satsuma’s intranasal drug contributed to some lift in operating income, and foreign exchange gains also contributed. Equity-method income from PPD also supported overall profitability.
Segment trends and investment/development
CRO: sales 7,537 million yen, operating income 1,538 million yen. TR: sales 59 million yen, operating loss 966 million yen. Medipolis: sales 237 million yen, operating income 16 million yen. Overseas order intake share increased and total orders on hand rose. As for future investments, EU experimental facilities expansion etc. continues.
Sales Trend
Operating Income Trend
Segment Sales
Forecast vs Actual
| Period | Sales | Operating income | Ordinary income |
|---|---|---|---|
| Q1 | 7,868 | 521 | 1,433 |
Shin Nippon Science Co., Ltd.
Company overview · Stock price · Financial data · All IR
